However, in the Keynote-028 and Keynote-158 studies of pembrolizumab (anti-PD1), PD-L1 expression, especially combined expression on tumor and immune stromal cells, was associated with improved response to pembrolizumab (35.7% vs. 6%) (19, 20). Here, CD274 is linked to neoplasm.